Navigation Links
Researchers at Mount Sinai Say a New Strain of Bird Flu Packs a Punch Even After It Becomes Resistant to Drugs
Date:12/10/2013

New York, NY (PRWEB) December 10, 2013

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza – the virus that causes the flu – appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.

It is not uncommon for influenza viruses to develop genetic mutations that make them less susceptible to anti-flu drugs. However, these mutations usually come at a cost to the virus, weakening its ability to replicate and to spread from one person to another.

Initial reports suggested that H7N9, an avian strain of influenza A that emerged in China last spring, could rapidly develop a mutation that made it resistant to treatment with the antiviral medication Tamiflu (oseltamivir). However, patients in whom drug resistance developed often had prolonged, severe infections and poor clinical outcomes. No vaccine is currently available to prevent H7N9, which infected at least 135 people and caused 44 deaths during the outbreak. In the absence of a vaccine, antiviral drugs are the only means of defense for patients who are infected with new strains of the flu.

“In this outbreak, we saw some differences in the behavior of H7N9 and other avian influenza strains that can infect humans, beginning with the rapid development of antiviral resistance in some people who were treated with oseltamivir and the persistence of high viral loads in those patients,” said lead investigator Nicole Bouvier, MD, Assistant Professor of Medicine, Infectious Diseases at the Icahn School of Medicine at Mount Sinai.

Specifically, the investigators found that a drug-resistant H7N9 virus retained its ability to replicate in human respiratory cells and was comparable to a non-resistant form of the virus in producing severe illness in animal models. And although H7N9 appears to have a limited ability to spread readily from human to human, transmissibility in animal models was comparable between drug-susceptible and drug-resistant strains. “Transmission was inefficient for both of the H7N9 viruses that we tested in our experiments,” said Dr. Bouvier. “But surprisingly, transmission of the drug-resistant virus was no less efficient than that of the drug-sensitive version.”

“Many of the people infected with H7N9 during the outbreak in China were elderly or had other conditions that predisposed them to severe influenza illness,” observed Dr. Bouvier. “Nevertheless, our study suggests that flu viruses can indeed develop drug-resistant mutations without suffering a penalty in terms of their own fitness.”

Older antiviral drugs such as amantadine are no longer effective in treating most strains of the flu that infect humans. Newer antiviral drugs called neuraminidase inhibitors block an enzyme that helps the virus replicate. These drugs include Tamiflu, a pill, and Relenza (zanamivir), a powder that is inhaled. Both medications have drawbacks: flu viruses can develop resistance to the medications in people who take them, and, in many parts of the world, neither drug is available in an intravenous form to treat those with severe infections.

“Our study underscores the need to develop a bigger arsenal of antiviral drugs and vaccines, which will allow us to outsmart the influenza virus,” said Dr. Bouvier. “Researchers at Mount Sinai are actively engaged in identifying new targets for drug therapy and are working to develop a universal vaccine that will prevent multiple strains of influenza.”

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.

For more information, visit Mount Sinai on the web, Facebook, Twitter or YouTube.

# # #

Read the full story at http://www.prweb.com/releases/2013/12/prweb11409427.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. OHSU researchers develop new drug approach that could lead to cures for wide range of diseases
2. Keep on exercising, researchers advise older breast cancer survivors
3. CU researchers may have discovered a plan to disable Menieres disease
4. Norwegian brain researchers share Horwitz prize
5. RI researchers validate tool for pain assessment in patients following cardiac surgery
6. University of California Researchers Validate Automated Breast Density Software
7. UAlberta researchers uncover why combination drug treatment ineffective in cancer clinical trials
8. Researchers identify fundamental differences between human cancers and genetically engineered mouse models of cancer
9. UEA researchers receive share of £1.26 million to reduce animal experimentation for drug development
10. Prostate cancer stem cells are a moving target, UCLA researchers say
11. Have researchers found a new treatment for sepsis?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, Deputy Governor ... Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest “Functional ... Tourism Products and Business at TAT said, “Thailand has long been recognized as ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance ... a new charity drive to generate community support for efforts to educate the local ... and treatments for all types of cancer. , Each day in America, roughly ...
(Date:8/18/2017)... ... 2017 , ... MLM Insurance Group, a Miami area provider ... is working to support the Take Stock In Children Foundation during a regional ... The Take Stock In Children Foundation (TSC) offers guidance and assistance to low ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Emotions are sacred, valid, honored, encouraged. ... Louis-based positive education company Generation Mindful. To help change the mindset of parents and ... emotional skills, she created the Time-In Toolkit, which launched on Kickstarter 3 weeks ago ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... , July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: ... southeast Michigan by Crain,s Detroit ... private and public companies by three-year revenue growth. This year,s ... To view the complete list, visit ... 50 is an incredible triumph," said Phil Hagerman , ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation ... Surgical System to support its strategic sales plan in ... and Virginia.  7D Surgical has entered into an exclusive sales ... medical facilities within those markets. ... Spartan Medical Purchases ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat company, ... a program for CleverCap LITE, a technology designed to ... to deliver innovative health technology solutions and services that ... CleverCap LITE offers medication monitoring ... bottle cover: Records ...
Breaking Medicine Technology: